No Data
No Data
Mesoblast Director's Holdings Surge Post-AGM
Mesoblast Issues 3.5M Unquoted Employee Options
Mesoblast Reports Unmet Conditions Lead to Cessation of Options
July 2024 ASX Leaders With High Insider Ownership And Strong Growth Prospects
Mesoblast Seeks FDA Nod for Pediatric GVHD Treatment
Mesoblast Resubmits Ryoncil Biologics License Application
Mesoblast (MESO) said late Monday it has resubmitted a biologics license application for approval of its experimental drug, Ryoncil, to treat children with steroid-refractory acute graft-versus-host d
101674396 : Hold or sell?
TrytosaveabitOP 101674396: Sorry I don’t give buy/sell advice! There’s no way for me to know others risk tolerance or the type of trade they are doing! I will say that I am still bullish on this! NFA JMO! GL